Wall Street brokerages expect MacroGenics, Inc. (NASDAQ:MGNX) to announce earnings of ($0.28) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for MacroGenics’ earnings. The lowest EPS estimate is ($1.03) and the highest is $1.45. MacroGenics reported earnings per share of ($0.94) during the same quarter last year, which would indicate a positive year-over-year growth rate of 70.2%. The company is expected to issue its next earnings results on Thursday, July 29th.
According to Zacks, analysts expect that MacroGenics will report full-year earnings of ($2.26) per share for the current year, with EPS estimates ranging from ($2.92) to ($0.95). For the next financial year, analysts forecast that the firm will report earnings of ($2.45) per share, with EPS estimates ranging from ($3.48) to ($1.72). Zacks’ EPS averages are a mean average based on a survey of analysts that follow MacroGenics.
MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings results on Thursday, April 29th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.37). The company had revenue of $16.88 million during the quarter, compared to analyst estimates of $31.16 million. MacroGenics had a negative net margin of 126.15% and a negative return on equity of 45.99%.
In related news, major shareholder Target N. V. Biotech acquired 75,000 shares of the company’s stock in a transaction that occurred on Monday, June 21st. The stock was acquired at an average price of $21.74 per share, for a total transaction of $1,630,500.00. Following the completion of the acquisition, the insider now owns 6,275,564 shares of the company’s stock, valued at approximately $136,430,761.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Thomas Spitznagel sold 5,000 shares of the company’s stock in a transaction dated Friday, July 16th. The shares were sold at an average price of $25.01, for a total value of $125,050.00. Following the completion of the sale, the senior vice president now owns 5,000 shares of the company’s stock, valued at approximately $125,050. The disclosure for this sale can be found here. Insiders own 7.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MGNX. Marshall Wace LLP bought a new stake in MacroGenics in the first quarter valued at about $80,000. Marshall Wace North America L.P. bought a new stake in MacroGenics in the first quarter valued at about $59,000. Los Angeles Capital Management LLC acquired a new position in MacroGenics in the fourth quarter valued at about $719,000. Bank of New York Mellon Corp grew its stake in MacroGenics by 5.3% in the fourth quarter. Bank of New York Mellon Corp now owns 225,633 shares of the biopharmaceutical company’s stock valued at $5,158,000 after acquiring an additional 11,417 shares during the period. Finally, Wells Fargo & Company MN grew its stake in MacroGenics by 137.9% in the fourth quarter. Wells Fargo & Company MN now owns 132,743 shares of the biopharmaceutical company’s stock valued at $3,034,000 after acquiring an additional 76,945 shares during the period. Institutional investors and hedge funds own 94.45% of the company’s stock.
MGNX traded down $0.07 during trading on Friday, hitting $25.43. The company’s stock had a trading volume of 11,204 shares, compared to its average volume of 630,870. The company’s 50 day moving average price is $26.75. MacroGenics has a 12 month low of $18.16 and a 12 month high of $36.48. The company has a market capitalization of $1.53 billion, a PE ratio of -10.28 and a beta of 2.27.
MacroGenics Company Profile
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
Read More: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.